No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing

Background BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, and previous studies have also suggested that rare protein truncating variants in BRIP1 are associated with an increased risk of breast cancer. These studies have led to inclusion of BRIP1 on targeted sequencing panels for breast cancer risk prediction. Methods We evaluated a truncating variant, p.Arg798Ter (rs137852986), and 10 missense variants of BRIP1, in 48 144 cases and 43 607 controls of European origin, drawn from 41 studies participating in the Breast Cancer Association Consortium (BCAC). Additionally, we sequenced the coding regions of BRIP1 in 13 213 cases and 5242 controls from the UK, 1313 cases and 1123 controls from three population-based studies as part of the Breast Cancer Family Registry, and 1853 familial cases and 2001 controls from Australia. Results The rare truncating allele of rs137852986 was observed in 23 cases and 18 controls in Europeans in BCAC (OR 1.09, 95% CI 0.58 to 2.03, p=0.79). Truncating variants were found in the sequencing studies in 34 cases (0.21%) and 19 controls (0.23%) (combined OR 0.90, 95% CI 0.48 to 1.70, p=0.75). Conclusions These results suggest that truncating variants in BRIP1 , and in particular p.Arg798Ter, are not associated with a substantial increase in breast cancer risk. Such observations have important implications for the reporting of results from breast cancer screening panels.

[1]  Lara E Sucheston-Campbell,et al.  Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. , 2015, Journal of the National Cancer Institute.

[2]  Kylie L. Gorringe,et al.  Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls , 2015, Breast Cancer Research.

[3]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[4]  Brigitte Rack,et al.  Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Nazneen Rahman,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[6]  Daniel J. Park,et al.  Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers. , 2014, Cancer discovery.

[7]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[8]  J. Hopper,et al.  Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study , 2014, Breast Cancer Research.

[9]  Paul D P Pharoah,et al.  Inherited genetic susceptibility to breast cancer: the beginning of the end or the end of the beginning? , 2013, The American journal of pathology.

[10]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[11]  J. Hopper,et al.  RAD51 and Breast Cancer Susceptibility: No Evidence for Rare Variant Association in the Breast Cancer Family Registry Study , 2012, PloS one.

[12]  D. Bowtell,et al.  A role for common genomic variants in the assessment of familial breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Radice,et al.  Germline mutations in BRIP1 and PALB2 in Jewish high cancer risk families , 2012, Familial Cancer.

[14]  Daniel J. Park,et al.  Rare mutations in XRCC2 increase the risk of breast cancer. , 2012, American journal of human genetics.

[15]  Heng Li,et al.  Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly , 2012, Bioinform..

[16]  O. Delaneau,et al.  A linear complexity phasing method for thousands of genomes , 2011, Nature Methods.

[17]  A. Gylfason,et al.  Mutations in BRIP1 confer high risk of ovarian cancer , 2011, Nature Genetics.

[18]  P. Oefner,et al.  Rare variants in the ATM gene and risk of breast cancer , 2011, Breast Cancer Research.

[19]  Marcel Martin.  Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[20]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[21]  R. Scott,et al.  BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer , 2011, Breast Cancer Research and Treatment.

[22]  J. Schleutker,et al.  Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals , 2011, Breast Cancer Research.

[23]  J. Hopper,et al.  Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study , 2011, Breast Cancer Research.

[24]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[25]  Alun Thomas,et al.  Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. , 2009, American journal of human genetics.

[26]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[27]  R. Warren,et al.  Genetic Models for the Familial Aggregation of Mammographic Breast Density , 2009, Cancer Epidemiology Biomarkers & Prevention.

[28]  Z. Shao,et al.  Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives , 2009, Breast Cancer Research and Treatment.

[29]  Catherine Voegele,et al.  Determining the effectiveness of High Resolution Melting analysis for SNP genotyping and mutation scanning at the TP53 locus , 2009, BMC Genetics.

[30]  D. Easton,et al.  Risk factors for the incidence of breast cancer: do they affect survival from the disease? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Simard,et al.  Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families , 2008, Journal of Human Genetics.

[32]  A. Uitterlinden,et al.  Kathleen Cuningham Foundation Consortium For Research Into Familial Breast Cancer , 2008 .

[33]  Alfons Meindl,et al.  BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study , 2007, BMC Cancer.

[34]  A. Whittemore,et al.  Population‐based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066–6T>G (IVS10–6T>G) from the Breast Cancer Family Registry , 2006, Human mutation.

[35]  Nazneen Rahman,et al.  Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles , 2006, Nature Genetics.

[36]  Nazneen Rahman,et al.  ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles , 2006, Nature Genetics.

[37]  C. Mathew,et al.  The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J , 2005, Nature Genetics.

[38]  S. Cantor,et al.  BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. , 2005, Cancer cell.

[39]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[40]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[41]  Norman Boyd,et al.  The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer , 2004, Breast Cancer Research.

[42]  Nazneen Rahman,et al.  Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations , 2002, Nature Genetics.

[43]  D. Sgroi,et al.  BACH1, a Novel Helicase-like Protein, Interacts Directly with BRCA1 and Contributes to Its DNA Repair Function , 2001, Cell.

[44]  D. Easton,et al.  ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. , 1998, American journal of human genetics.